… Oral afatinib had a manageable tolerability profile. EGFR-mediated adverse … afatinib is a
valuable new option for use in treatment-naïve or EGFR TKI-naïve patients with advanced lung …

… preclinical activity in non-small-cell lung cancer (NSCLC) with EGFR mutations. We aimed
to assess the efficacy of afatinib in patients with lung adenocarcinoma and EGFR mutations. …

… Afatinib was recently approved in the US and the EU for the treatment of advanced … of
afatinib in patients with advanced NSCLC and activating EGFR mutations and in patients with …

… studies in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or
gefitinib. The decision to use afatinib as a frontline treatment for EGFR-mutant patients will likely …

… of afatinib in patients with advanced non-small-cell lung cancer … Afatinib was active in
non-small-cell lung cancer tumours that … Clinical benefit was lower in patients with de-novo …

… LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer
who progressed during prior treatment with erlotinib, gefitinib, or both. Journal of clinical …

… , in LUX-Lung 6 trial patients treated with afatinib had better … , patients with common mutations
treated with afatinib had a … OS benefit of afatinib was driven by patients harboring exon 19 …

… line afatinib in EGFR mutation-positive lung cancer, that have included also 75 patients with
uncommon mutations, showed a limited activity (response rate 8–14%) of afatinib in patients …

… The aim of the present article is to critically review the clinical trials exploring afatinib efficacy
in lung cancer and to compare, when possible, this novel agent to available treatments. …

… in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials
of afatinib in EGFR mutation-positive lung cancer. J Thorac Oncol 2013;8(Suppl):abstract O03…